GLP-1 Drugs and Microvascular Disease: Eye, Kidney, and Nerve Protection
Study of GLP-1 drug effects on microvascular outcomes examines protection of small blood vessels in eyes, kidneys, and nerves in diabetes.
Quick Facts
What This Study Found
Study of GLP-1 drug effects on microvascular outcomes examines protection of small blood vessels in eyes, kidneys, and nerves in diabetes.
Key Numbers
4 RCTs included, over 27,000 patients total. Follow-up: 32 weeks to 5.4 years. Consistent renal protection; possible retinopathy signal.
How They Did This
In publication.
Why This Research Matters
Relevant to peptide therapeutics.
The Bigger Picture
Advances peptide evidence.
What This Study Doesn't Tell Us
In publication.
Questions This Raises
- ?Long-term implications?
- ?Evidence comparison?
- ?Next steps?
Trust & Context
- Key Stat:
- Key finding Study of GLP-1 drug effects on microvascular outcomes examines protection of small blood vessels in
- Evidence Grade:
- Based on design.
- Study Age:
- Published in 2025.
- Original Title:
- Microvascular Outcomes of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Type 2 Diabetes: A Systematic Review of Retinopathy and Nephropathy Evidence.
- Published In:
- Cureus, 17(9), e92976 (2025)
- Authors:
- Arif, Atia, Lama, Sanu, Singla, Bhavna, Singla, Shivam, Kumawat, Sunita, Tharwani, Anusha, Usman, Muhammad, Khalid, Hamna, Kanukollu, Venkata Madusudana Rao, Ekomwereren, Osatohanmwen, Khan, Shabir
- Database ID:
- RPEP-09975
Evidence Hierarchy
Combines results from multiple studies to find an overall pattern.
What do these levels mean? →Frequently Asked Questions
What does this mean?
Study of GLP-1 drug effects on microvascular outcomes examines protection of small blood vessels in eyes, kidneys, and nerves in diabetes.
How reliable?
Consult publication.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09975APA
Arif, Atia; Lama, Sanu; Singla, Bhavna; Singla, Shivam; Kumawat, Sunita; Tharwani, Anusha; Usman, Muhammad; Khalid, Hamna; Kanukollu, Venkata Madusudana Rao; Ekomwereren, Osatohanmwen; Khan, Shabir. (2025). Microvascular Outcomes of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Type 2 Diabetes: A Systematic Review of Retinopathy and Nephropathy Evidence.. Cureus, 17(9), e92976. https://doi.org/10.7759/cureus.92976
MLA
Arif, Atia, et al. "Microvascular Outcomes of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Type 2 Diabetes: A Systematic Review of Retinopathy and Nephropathy Evidence.." Cureus, 2025. https://doi.org/10.7759/cureus.92976
RethinkPeptides
RethinkPeptides Research Database. "Microvascular Outcomes of Glucagon-Like Peptide-1 (GLP-1) Re..." RPEP-09975. Retrieved from https://rethinkpeptides.com/research/arif-2025-microvascular-outcomes-of-glucagonlike
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.